Evidence map›Paper›PMID 35413962›Full record

ArticleScientific reports2022

Meiotic drive in chronic lymphocytic leukemia compared with other malignant blood disorders.

Viggo Jønsson, Haneef Awan, Neil Deaton Jones, Tom Børge Johannesen, Klaus Thøgersen, Bjarni Á Steig, Gudrid Andorsdottir, Geir Erland Tjønnfjord

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Viggo JønssonDepartment of Hematology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Nydalen, P.O. box 4950, 0424, Oslo, Norway. Viggo.jonsson@medisin.uio.no.
Haneef AwanCenter for Information Technology Service (USIT), Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Blindern, P.O. box 1059, 0316, Oslo, Norway.
Neil Deaton JonesDepartment of Computer Science, University of Copenhagen, Universitetsparken5, Building B, 2100, Copenhagen, Denmark.
Tom Børge JohannesenNorwegian Cancer Registry, Ullernchausseen 64, 0379, Oslo, Norway.
Klaus ThøgersenTechnology, Product Development, Medical Device Development (TPU Ltd.), Mølledamsvej 10, 3460, Birkerød, Denmark.
Bjarni Á SteigNational Hospital of the Faroe Islands, Medical Department, J.C. Svaboe gøta 2, F 100, Torshavn, Faroe Islands.
Gudrid AndorsdottirGenetic Biobank of the Faroe Islands, J.C. Svaboe gøta 43, 100, Torshavn, Faroe Islands.
Geir Erland TjønnfjordDepartment of Hematology, Oslo University Hospital and K.G, Jebsen Center for B-Cell Malignancies and Institute of Clinical Medicine, University of Oslo, Nydalen, P.O. box 4950, 0424, Oslo, Norway.
Oslo University Hospital · NOUniversity of the Faroe Islands · FOCancer Registry of Norway · NOUniversity of Copenhagen · DKUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heredity of the malignant blood disorders, leukemias, lymphomas and myeloma, has so far been largely unknown. The present study comprises genealogical investigations of one hundred and twelve Scandinavian families with unrelated parents and two or more cases of malignant blood disease. For comparison, one large family with related family members and three hundred and forty-one cases of malignant blood disease from the Faroese population was included. The inheritance is non-Mendelian, a combination of genomic parental imprinting and feto-maternal microchimerism. There is significantly more segregation in maternal than in paternal lines, predominance of mother-daughter combinations in maternal lines, and father-son combinations in paternal lines. Chronic lymphocytic leukemia is the most frequent diagnosis in the family material, and chronic lymphocytic leukemia has a transgenerational segregation that is unique in that inheritance of susceptibility to chronic lymphocytic leukemia is predominant in males of paternal lines. Male offspring with chronic lymphocytic leukemia in paternal lines have a birth-order effect, which is manifest by the fact that there are significantly more male patients late in the sibling line. In addition, there is contravariation in chronic lymphocytic leukemia, i.e. lower occurrence than expected in relation to other diagnoses, interpreted in such a way that chronic lymphocytic leukemia remains isolated in the pedigree in relation to other diagnoses of malignant blood disease. Another non-Mendelian function appears in the form of anticipation, i.e. increased intensity of malignancy down through the generations and a lower age at onset of disease than otherwise seen in cases from the Cancer Registers, in acute lymphoblastic leukemia, for example. It is discussed that this non-Mendelian segregation seems to spread the susceptibility genes depending on the gender of the parents and not equally to all children in the sibling line, with some remaining unaffected by susceptibility i.e. "healthy and unaffected", due to a birth order effect. In addition, anticipation is regarded as a non-Mendelian mechanism that can amplify, «preserve» these vital susceptibility genes in the family. Perhaps this segregation also results in a sorting of the susceptibility, as the percentage of follicular lymphoma and diffuse large B-cell lymphoma is lower in the family material than in an unselected material. Although leukemias, lymphomas and myelomas are potentially fatal diseases, this non-Mendelian distribution and amplification hardly play any quantitative role in the survival of Homo sapiens, because these diseases mostly occur after fertile age.

Indexed as

LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMultiple MyelomaChildFathersHumansMalePedigree

Identifiers

PMID35413962
PMCPMC9005523
OpenAlexW4225406328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.